表皮生长因子受体抑制剂相关甲沟炎的研究进展  

Epidermal growth factor receptor inhibitor-related paronychia

作　　者：胡紫馨 谭可欣[1,2] 董慧静 张旭 俞仪萱[1,2] 鲁星妤[1,2] 李嘉 崔慧娟 Hu Zixin;Tan Kexin;Dong Huijing;Zhang Xu;Yu Yixuan;Lu Xingyu;Li Jia;Cui Huijuan(Beijing University of Chinese Medicine,Beijing 100029,China;Department of Oncology,China-Japan Friendship Hospital,Beijing 100029,China)

机构地区：[1]北京中医药大学,北京100029 [2]中日友好医院中西医结合肿瘤内科,北京100029

出　　处：《中华皮肤科杂志》2025年第3期276-281,共6页Chinese Journal of Dermatology

基　　金：国家自然科学基金(81873396);首都卫生发展科研专项项目(首发2018-2-4065)。

摘　　要：表皮生长因子受体抑制剂(EGFRI)相关甲沟炎是指与EGFRI治疗明确相关的以甲周皮肤红斑、水肿、脓性渗出、甲周或甲下肉芽组织病变,或伴甲板变薄变脆甚至碎裂分离为特点的疾病。表皮功能抑制、炎症形成并继发感染、血管新生是EGFRI相关甲沟炎发生发展的核心过程。本文综述EGFRI相关甲沟炎的流行病学、发病机制、临床表现、预防和治疗手段。Epidermal growth factor receptor inhibitor(EGFRI)-related paronychia is a condition clearly related to EGFRI therapy,characterized by periungual erythema,edema,purulent exudates,periungual or subungual granulomatous lesions,and sometimes accompanied by thinning,fragility or even splitting and seperation of nail plates.Inhibition of epidermal function,inflammation and secondary infections,as well as angiogenesis are the core processes in the occurrence and development of EGFRI-related paronychia.This review summarizes epidemiology,pathogenesis,clinical manifestations,prevention and treatment of EGFRI-related paronychia.

关 键 词：甲沟炎 表皮生长因子受体抑制剂 皮肤毒性反应 

分 类 号：R63[医药卫生—外科学]